z-logo
Premium
Divergence in NK cell and cyclic AMP regulation of T cell CD40L expression in asthmatic subjects
Author(s) -
Wingett Denise,
Nielson Christopher P.
Publication year - 2003
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.0303103
Subject(s) - cd40 , biology , t cell , interleukin 21 , cyclic adenosine monophosphate , cell , immunology , endocrinology , medicine , receptor , immune system , cytotoxic t cell , in vitro , biochemistry
T cells are central in the pathogenesis of asthma, and the associated ligand, CD40L, plays an important role by increasing production of immunoglobulin E and inflammatory mediators. β‐Adrenoceptor agonists are commonly used in asthma, although little is known regarding effects on CD40L expression and T cell activation. Here, we demonstrate that cyclic adenosine monophosphate (cAMP) and β‐adrenoceptor agonists differentially regulate CD40L in asthma. cAMP increased naïve T cell CD40L expression in asthmatics (9.8±8.5 increase in percent CD40L‐positive cells), and expression in control subjects was inhibited (7.1±6.0 decrease in percent CD40L‐positive cells; P < 0.05). Cell depletion and reconstitution experiments were used to determine that cAMP enhancement of CD40L required cell‐to‐cell contact with an asthma‐associated natural killer (NK) cell subset. The NK cell subset expressed elevated levels of CD95, and in vitro‐generated CD95 + NK2 cells also produced similar effects on CD40L expression. Our findings suggest that a subset of NK cells with elevated CD95 expression is associated with asthma and can reverse cAMP inhibitory effects on T cell CD40L with the potential to increase disease exacerbation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here